Medpace Holdings Inc Stock
Medpace Holdings Inc Stock
We can see a decrease in the price for Medpace Holdings Inc. Compared to yesterday it has lost -€6.300 (-1.310%).
With 5 Buy predictions and 5 Sell predictions the community is currently undecided on Medpace Holdings Inc.
With a target price of 416 € there is a slightly negative potential of -12.48% for Medpace Holdings Inc compared to the current price of 475.3 €.
So far the community has only identified positive things for Medpace Holdings Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Medpace Holdings Inc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medpace Holdings Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medpace Holdings Inc | -1.310% | 0.999% | -7.923% | 43.292% | 47.015% | 136.821% | 313.304% |
| Galapagos N.V. | -1.220% | -0.295% | -3.156% | 5.304% | 2.662% | -25.824% | -72.449% |
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
Medpace Holdings, Inc. (MEDP) demonstrates a strong financial position as of Q2 2025, with key highlights including:
The overall financial trend is positive, driven by revenue growth and improving profitability.
Investors should consider these factors when evaluating Medpace Holdings, Inc., weighing the company's strong revenue and net income growth against its cash management and liquidity position.
Comments
Medpace (NASDAQ:MEDP) had its price target raised by analysts at TD Cowen from $356.00 to $462.00. They now have a "sell" rating on the stock.
Show more
Ratings data for MEDP provided by MarketBeat
Medpace (NASDAQ:MEDP) had its "sell" rating reaffirmed by analysts at Cowen Inc.
Show more
Ratings data for MEDP provided by MarketBeat
Medpace (NASDAQ:MEDP) had its price target raised by analysts at Mizuho from $575.00 to $655.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MEDP provided by MarketBeat